Analysis of Long-term (Investment) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Johnson & Johnson, long-term (investment) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The analysis of long-term activity ratios reveals a general decline in asset and equity utilization efficiency over the period from April 2022 to June 2026. While initial quarters showed peak performance, a gradual contraction in turnover rates is evident across all three key metrics, suggesting a decrease in the capacity of the investment base to generate proportional revenue.
- Net Fixed Asset Turnover
- A sustained downward trajectory is observed, with the ratio decreasing from a peak of 5.29 in October 2022 to 4.15 by June 2026. This trend indicates a reduction in the revenue generated per unit of net fixed assets, which may suggest that recent capital expenditures have not yet resulted in corresponding sales growth or that the productivity of fixed assets has diminished.
- Total Asset Turnover
- The total asset turnover remains relatively stable but exhibits a slight overall decline, moving from 0.53 in April 2022 to 0.49 in June 2026. The ratio fluctuated within a narrow range, reaching a maximum of 0.55 in October 2022 and a minimum of 0.46 in March 2025, reflecting a minor but consistent erosion in the overall efficiency of the total asset base in supporting sales volume.
- Equity Turnover
- Equity turnover demonstrates a moderate decrease over the analyzed timeframe, starting at 1.27 in April 2022 and concluding at 1.15 in June 2026. After reaching a peak of 1.30 in April 2023, the ratio experienced a decline, reaching a low of 1.14 in March 2025 before stabilizing. This indicates a reduction in the efficiency with which shareholder equity is being leveraged to drive revenue.
AI Ask an analyst for more
Net Fixed Asset Turnover
Johnson & Johnson, net fixed asset turnover calculation (quarterly data)
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Sales to customers | 25,310) | 24,062) | 24,564) | 23,993) | 23,743) | 21,893) | 22,520) | 22,471) | 22,447) | 21,383) | 21,395) | 21,351) | 21,519) | 20,894) | 23,706) | 23,791) | 24,020) | 23,426) | ||||||
| Property, plant and equipment, net | 23,582) | 23,270) | 23,169) | 22,338) | 21,949) | 20,871) | 20,518) | 20,479) | 19,748) | 19,632) | 19,898) | 18,821) | 20,576) | 20,174) | 19,803) | 18,152) | 18,354) | 18,701) | ||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Net fixed asset turnover1 | 4.15 | 4.14 | 4.07 | 4.13 | 4.13 | 4.28 | 4.33 | 4.28 | 4.38 | 4.36 | 4.28 | 4.65 | 4.37 | 4.58 | 4.79 | 5.29 | 5.21 | 5.07 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | 11.11 | 11.05 | 10.87 | 10.88 | 11.04 | 10.95 | 10.97 | 10.80 | 10.95 | 10.92 | 10.89 | 11.18 | 11.33 | 11.51 | 11.76 | 11.82 | 11.57 | 11.18 | ||||||
| Amgen Inc. | 4.24 | 4.32 | 4.44 | 4.78 | 4.89 | 4.91 | 4.89 | 5.06 | 4.85 | 4.70 | 4.53 | 4.61 | 4.58 | 4.56 | 4.57 | 4.73 | 4.77 | 4.75 | ||||||
| Bristol-Myers Squibb Co. | 6.31 | 6.33 | 6.39 | 6.54 | 6.47 | 6.60 | 6.77 | 6.87 | 6.79 | 6.75 | 6.77 | 6.93 | 7.11 | 7.30 | 7.38 | 7.74 | 7.90 | 7.77 | ||||||
| Danaher Corp. | 4.31 | 4.53 | 4.44 | 4.51 | 4.52 | 4.66 | 4.78 | 4.90 | 5.08 | 5.20 | 5.25 | 6.01 | 6.68 | 7.31 | 7.96 | 8.40 | 8.12 | 7.94 | ||||||
| Eli Lilly & Co. | 2.72 | 2.72 | 2.64 | 2.66 | 2.59 | 2.65 | 2.63 | 2.53 | 2.62 | 2.64 | 2.64 | 2.70 | 2.62 | 2.63 | 2.81 | 3.14 | 3.18 | 3.22 | ||||||
| Gilead Sciences Inc. | 5.11 | 5.19 | 5.16 | 5.19 | 5.26 | 5.27 | 5.28 | 5.22 | 5.17 | 5.13 | 5.07 | 4.88 | 4.91 | 4.88 | 4.93 | 5.01 | 5.13 | 5.18 | ||||||
| Merck & Co. Inc. | 2.59 | 2.59 | 2.57 | 2.51 | 2.52 | 2.58 | 2.70 | 2.69 | 2.69 | 2.66 | 2.61 | 2.63 | 2.62 | 2.66 | 2.77 | 2.89 | 2.85 | 2.73 | ||||||
| Pfizer Inc. | 3.35 | 3.26 | 3.24 | 3.33 | 3.40 | 3.40 | 3.46 | 3.26 | 2.97 | 2.98 | 3.14 | 3.88 | 4.48 | 5.46 | 6.17 | 6.47 | 6.64 | 6.12 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.85 | 2.83 | 2.80 | 2.85 | 2.94 | 3.00 | 3.09 | 3.12 | 3.13 | 3.10 | 3.16 | 3.27 | 3.23 | 3.19 | 3.23 | 3.70 | 3.91 | 4.64 | ||||||
| Thermo Fisher Scientific Inc. | 4.31 | 4.24 | 4.22 | 4.30 | 4.48 | 4.60 | 4.61 | 4.50 | 4.56 | 4.56 | 4.54 | 4.74 | 4.68 | 4.68 | 4.84 | 5.12 | 5.02 | 4.87 | ||||||
| Vertex Pharmaceuticals Inc. | 7.56 | 7.60 | 7.89 | 8.23 | 8.55 | 8.57 | 8.98 | 9.51 | 8.61 | 8.68 | 8.51 | 8.59 | 8.47 | 8.28 | 8.06 | 7.78 | 7.59 | 7.18 | ||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Net fixed asset turnover
= (Sales to customersQ2 2026
+ Sales to customersQ1 2026
+ Sales to customersQ4 2025
+ Sales to customersQ3 2025)
÷ Property, plant and equipment, net
= (25,310 + 24,062 + 24,564 + 23,993)
÷ 23,582 = 4.15
2 Click competitor name to see calculations.
The analysis of long-term investment activity reveals a general decline in asset utilization efficiency over the observed period, characterized by an initial peak followed by a sustained correction and eventual stabilization.
- Net Fixed Asset Turnover Trend
- A downward trend in the net fixed asset turnover ratio is evident, moving from a peak of 5.29 in October 2022 to a stabilized range between 4.07 and 4.15 by the end of the period in June 2026. This decline indicates that the company is generating less revenue per unit of net fixed asset investment compared to the early 2022 period.
- Revenue and Asset Correlation
- Between April 2022 and April 2023, a significant contraction in sales occurred, with quarterly revenues dropping from approximately 23.4 billion USD to 20.9 billion USD. During this same window, net property, plant, and equipment generally increased, which contributed to the sharp decrease in the turnover ratio from 5.07 to 4.58.
- Investment Growth and Stabilization
- From 2024 through 2026, a period of proportional growth is observed. While sales recovered and grew steadily from 21.4 billion USD in March 2024 to 25.3 billion USD in June 2026, net property, plant, and equipment also rose consistently from 19.6 billion USD to 23.6 billion USD. This concurrent growth resulted in the turnover ratio flattening, maintaining a consistent level around 4.1 to 4.3.
- Operational Efficiency Insight
- The transition from a turnover ratio above 5.0 to a stabilized rate near 4.1 suggests a structural shift in the asset base. The increase in net fixed assets has outpaced the growth in sales, suggesting either a period of heavy capital expenditure intended for future capacity or a decrease in the efficiency of existing long-term assets.
AI Ask an analyst for more
Total Asset Turnover
Johnson & Johnson, total asset turnover calculation (quarterly data)
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Sales to customers | 25,310) | 24,062) | 24,564) | 23,993) | 23,743) | 21,893) | 22,520) | 22,471) | 22,447) | 21,383) | 21,395) | 21,351) | 21,519) | 20,894) | 23,706) | 23,791) | 24,020) | 23,426) | ||||||
| Total assets | 201,061) | 200,894) | 199,210) | 192,816) | 193,389) | 193,671) | 180,104) | 178,287) | 181,088) | 171,966) | 167,558) | 166,061) | 191,686) | 195,969) | 187,378) | 175,124) | 177,724) | 178,355) | ||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Total asset turnover1 | 0.49 | 0.48 | 0.47 | 0.48 | 0.47 | 0.46 | 0.49 | 0.49 | 0.48 | 0.50 | 0.51 | 0.53 | 0.47 | 0.47 | 0.51 | 0.55 | 0.54 | 0.53 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | 0.48 | 0.46 | 0.46 | 0.45 | 0.43 | 0.42 | 0.42 | 0.39 | 0.39 | 0.37 | 0.40 | 0.40 | 0.41 | 0.42 | 0.42 | 0.41 | 0.40 | 0.40 | ||||||
| Amgen Inc. | 0.38 | 0.38 | 0.39 | 0.38 | 0.38 | 0.37 | 0.35 | 0.34 | 0.32 | 0.30 | 0.28 | 0.28 | 0.28 | 0.28 | 0.38 | 0.38 | 0.41 | 0.41 | ||||||
| Bristol-Myers Squibb Co. | 0.56 | 0.56 | 0.54 | 0.50 | 0.50 | 0.52 | 0.52 | 0.51 | 0.49 | 0.46 | 0.47 | 0.49 | 0.48 | 0.49 | 0.48 | 0.48 | 0.47 | 0.46 | ||||||
| Danaher Corp. | 0.27 | 0.30 | 0.29 | 0.30 | 0.29 | 0.30 | 0.31 | 0.29 | 0.30 | 0.28 | 0.28 | 0.29 | 0.33 | 0.35 | 0.37 | 0.39 | 0.38 | 0.36 | ||||||
| Eli Lilly & Co. | 0.56 | 0.62 | 0.58 | 0.52 | 0.53 | 0.55 | 0.57 | 0.54 | 0.54 | 0.56 | 0.53 | 0.55 | 0.54 | 0.52 | 0.58 | 0.62 | 0.62 | 0.62 | ||||||
| Gilead Sciences Inc. | 0.60 | 0.52 | 0.49 | 0.49 | 0.52 | 0.51 | 0.48 | 0.52 | 0.52 | 0.48 | 0.43 | 0.44 | 0.44 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | ||||||
| Merck & Co. Inc. | 0.51 | 0.51 | 0.47 | 0.50 | 0.54 | 0.56 | 0.55 | 0.54 | 0.55 | 0.58 | 0.56 | 0.56 | 0.56 | 0.54 | 0.54 | 0.55 | 0.53 | 0.51 | ||||||
| Pfizer Inc. | 0.32 | 0.30 | 0.30 | 0.30 | 0.31 | 0.30 | 0.30 | 0.28 | 0.26 | 0.25 | 0.26 | 0.32 | 0.36 | 0.48 | 0.51 | 0.51 | 0.52 | 0.50 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.37 | 0.37 | 0.35 | 0.35 | 0.37 | 0.38 | 0.38 | 0.37 | 0.37 | 0.38 | 0.40 | 0.41 | 0.41 | 0.41 | 0.42 | 0.50 | 0.52 | 0.63 | ||||||
| Thermo Fisher Scientific Inc. | 0.41 | 0.40 | 0.40 | 0.42 | 0.43 | 0.43 | 0.44 | 0.42 | 0.43 | 0.44 | 0.43 | 0.45 | 0.46 | 0.46 | 0.46 | 0.49 | 0.47 | 0.44 | ||||||
| Vertex Pharmaceuticals Inc. | 0.46 | 0.46 | 0.47 | 0.47 | 0.48 | 0.49 | 0.49 | 0.48 | 0.51 | 0.43 | 0.43 | 0.44 | 0.47 | 0.49 | 0.49 | 0.52 | 0.54 | 0.56 | ||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Total asset turnover
= (Sales to customersQ2 2026
+ Sales to customersQ1 2026
+ Sales to customersQ4 2025
+ Sales to customersQ3 2025)
÷ Total assets
= (25,310 + 24,062 + 24,564 + 23,993)
÷ 201,061 = 0.49
2 Click competitor name to see calculations.
The analysis of total asset turnover from April 2022 through June 2026 reveals a general contraction in asset utilization efficiency, characterized by a transition from peak values in late 2022 to a stabilized lower range throughout 2024 and 2025.
- Revenue Trends
- Sales to customers exhibited volatility over the analyzed period, starting at 23,426 million USD in April 2022 and experiencing a notable decline during the first half of 2023, reaching a low of 20,894 million USD. A consistent recovery followed, with revenue trending upward from 2024 onward and peaking at 25,310 million USD by June 2026.
- Asset Base Fluctuations
- Total assets demonstrated significant variation, initially fluctuating between 175,124 million USD and 187,378 million USD. A sharp contraction occurred in October 2023, where assets fell to a period low of 166,061 million USD. Subsequently, the asset base entered a period of steady expansion, growing to 201,061 million USD by June 2026, indicating a substantial increase in the total investment base.
- Asset Turnover Performance
- The total asset turnover ratio reached its maximum of 0.55 in October 2022. A subsequent downward trend was observed, with the ratio reaching a minimum of 0.46 in March 2025. A temporary spike to 0.53 in October 2023 is identified as a result of the sudden reduction in total assets rather than a surge in sales. In the final quarters of the period, the ratio stabilized between 0.47 and 0.49, suggesting that revenue growth did not proportionally match the expansion of the asset base.
Overall, the data indicates a decline in operational efficiency regarding asset usage. The reduction in the turnover ratio suggests that each unit of assets generated less revenue toward the end of the period than at the beginning, reflecting a strategic or operational phase where asset growth outpaced sales growth.
AI Ask an analyst for more
Equity Turnover
Johnson & Johnson, equity turnover calculation (quarterly data)
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Sales to customers | 25,310) | 24,062) | 24,564) | 23,993) | 23,743) | 21,893) | 22,520) | 22,471) | 22,447) | 21,383) | 21,395) | 21,351) | 21,519) | 20,894) | 23,706) | 23,791) | 24,020) | 23,426) | ||||||
| Total Johnson & Johnson shareholders’ equity | 84,971) | 81,186) | 81,544) | 79,277) | 78,473) | 78,109) | 71,490) | 70,158) | 71,538) | 70,020) | 68,774) | 71,228) | 75,149) | 70,869) | 76,804) | 74,599) | 76,357) | 74,709) | ||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Equity turnover1 | 1.15 | 1.19 | 1.16 | 1.16 | 1.15 | 1.14 | 1.24 | 1.25 | 1.21 | 1.22 | 1.24 | 1.23 | 1.20 | 1.30 | 1.24 | 1.29 | 1.25 | 1.27 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | 40.40 | 16.94 | 9.21 | 8.11 | 6.79 | 5.24 | 4.56 | 4.35 | 4.27 | 3.36 | 3.62 | 3.91 | 3.48 | ||||||
| Amgen Inc. | 3.10 | 3.86 | 4.06 | 3.59 | 4.51 | 5.28 | 5.45 | 4.14 | 4.99 | 5.61 | 4.32 | 3.35 | 3.73 | 4.66 | 6.77 | 6.71 | 10.17 | 26.68 | ||||||
| Bristol-Myers Squibb Co. | 2.20 | 2.42 | 2.61 | 2.59 | 2.74 | 2.74 | 2.96 | 2.77 | 2.73 | 2.76 | 1.53 | 1.55 | 1.41 | 1.44 | 1.49 | 1.43 | 1.45 | 1.49 | ||||||
| Danaher Corp. | 0.48 | 0.47 | 0.47 | 0.48 | 0.46 | 0.47 | 0.48 | 0.46 | 0.47 | 0.44 | 0.45 | 0.49 | 0.54 | 0.58 | 0.63 | 0.67 | 0.66 | 0.65 | ||||||
| Eli Lilly & Co. | 2.35 | 2.32 | 2.46 | 2.50 | 2.91 | 3.11 | 3.17 | 2.87 | 2.87 | 2.80 | 3.17 | 2.86 | 2.67 | 2.47 | 2.68 | 2.90 | 3.40 | 3.14 | ||||||
| Gilead Sciences Inc. | 2.52 | 1.24 | 1.27 | 1.33 | 1.46 | 1.49 | 1.48 | 1.52 | 1.51 | 1.56 | 1.18 | 1.22 | 1.28 | 1.27 | 1.27 | 1.27 | 1.34 | 1.37 | ||||||
| Merck & Co. Inc. | 1.59 | 1.43 | 1.24 | 1.24 | 1.30 | 1.32 | 1.39 | 1.42 | 1.43 | 1.52 | 1.60 | 1.44 | 1.51 | 1.24 | 1.29 | 1.33 | 1.32 | 1.32 | ||||||
| Pfizer Inc. | 0.75 | 0.70 | 0.72 | 0.68 | 0.72 | 0.69 | 0.72 | 0.65 | 0.64 | 0.61 | 0.67 | 0.71 | 0.79 | 0.92 | 1.05 | 1.08 | 1.16 | 1.12 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.49 | 0.47 | 0.46 | 0.46 | 0.47 | 0.48 | 0.48 | 0.47 | 0.48 | 0.49 | 0.51 | 0.53 | 0.53 | 0.53 | 0.54 | 0.64 | 0.69 | 0.83 | ||||||
| Thermo Fisher Scientific Inc. | 0.88 | 0.87 | 0.83 | 0.86 | 0.86 | 0.87 | 0.86 | 0.86 | 0.89 | 0.93 | 0.92 | 0.96 | 0.99 | 1.04 | 1.02 | 1.01 | 1.01 | 1.00 | ||||||
| Vertex Pharmaceuticals Inc. | 0.62 | 0.63 | 0.64 | 0.68 | 0.66 | 0.67 | 0.67 | 0.68 | 0.70 | 0.55 | 0.56 | 0.58 | 0.61 | 0.64 | 0.64 | 0.67 | 0.70 | 0.73 | ||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Equity turnover
= (Sales to customersQ2 2026
+ Sales to customersQ1 2026
+ Sales to customersQ4 2025
+ Sales to customersQ3 2025)
÷ Total Johnson & Johnson shareholders’ equity
= (25,310 + 24,062 + 24,564 + 23,993)
÷ 84,971 = 1.15
2 Click competitor name to see calculations.
The analysis of equity turnover from April 2022 through June 2026 reveals a general downward trajectory in the efficiency of equity utilization, characterized by a shift in the relationship between revenue generation and the company's capital base.
- Sales Performance Trends
- Revenue exhibited volatility between 2022 and 2023, with quarterly sales declining from a peak of 24,020 million USD in July 2022 to a low of 20,894 million USD in April 2023. However, a consistent recovery phase began in 2024, culminating in a growth trend through 2026, where quarterly sales reached a period high of 25,310 million USD by June 28, 2026.
- Shareholders' Equity Evolution
- The equity base showed significant fluctuation in 2023, reaching a minimum of 68,774 million USD in December 2023. Following this trough, there was a sustained increase in total shareholders' equity. By the end of the observed period in June 2026, equity had expanded to 84,971 million USD, representing a substantial increase in the company's long-term funding base.
- Equity Turnover Ratio Dynamics
- The equity turnover ratio remained relatively stable between 1.20 and 1.30 from April 2022 through December 2024. A distinct decline is observed starting in March 2025, where the ratio dropped to 1.14 and remained suppressed, fluctuating between 1.14 and 1.19 through June 2026. This compression indicates that the growth in the equity base has outpaced the growth in sales, leading to a reduction in the revenue generated per unit of equity.
Overall, while the company achieved higher absolute sales figures in 2026 compared to 2022, the increased accumulation of equity has resulted in a lower asset turnover efficiency regarding shareholders' funds. The transition from a ratio peak of 1.30 in early 2023 to 1.15 in June 2026 suggests a more capital-intensive position or a slower rate of revenue scaling relative to equity growth.
AI Ask an analyst for more